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Lately, much effort has been made to find mRNA biomarkers for tuberculosis (TB)
disease/infection with microarray-based approaches. In a pilot investigation, through
RNA sequencing technology, we observed a prominent modulation of DOCK9, EPHA4,
and NPC2 mRNA abundance in the blood of TB patients. To corroborate these
findings, independent validations were performed in cohorts from different areas. Gene
expression levels in blood were evaluated by quantitative real-time PCR (Brazil, n = 129)
or reanalysis of public microarray data (UK: n = 96; South Africa: n = 51; Germany:
n = 26; and UK/France: n = 63). In the Brazilian cohort, significant modulation of all
target-genes was observed comparing TB vs. healthy recent close TB contacts (rCt).
With a 92% specificity, NPC2 mRNA high expression (NPC2high) showed the highest
sensitivity (85%, 95% CI 65%–96%; area under the ROC curve [AUROC] = 0.88),
followed by EPHA4 (53%, 95% CI 33%–73%, AUROC = 0.73) and DOCK9 (19%,
95% CI 7%–40%; AUROC = 0.66). All the other reanalyzed cohorts corroborated the
potential of NPC2high as a biomarker for TB (sensitivity: 82–100%; specificity: 94–97%).
An NPC2high profile was also observed in 60% (29/48) of the tuberculin skin test positive
rCt, and additional follow-up evaluation revealed changes in the expression levels of
NPC2 during the different stages of Mycobacterium tuberculosis infection, suggesting
that further studies are needed to evaluate modulation of this gene during latent TB
and/or progression to active disease. Considering its high specificity, our data indicate,
for the first time, that NPC2high might serve as an accurate single-gene biomarker for TB.
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INTRODUCTION
Mycobacterium tuberculosis bacilli spread through the air, and
the lung parenchyma is the main site of infection. Despite
the availability of effective treatment, new tuberculosis (TB)
cases are commonly mis- or under-diagnosed, leading to
delayed initiation of chemotherapy and, consequently, to high
morbidity and mortality (Golub et al., 2005; Belay et al., 2012).
The diagnosis of pulmonary TB relies on the combination
of clinical and epidemiological features associated with chest
radiographic changes and microbiological findings (detection of
acid-fast bacilli, culture growth or nucleic acid detection; Sia
and Wieland, 2011). Nevertheless, the sputum smear lacks in
sensitivity (50–70%), and the more sensitive culture (80–89%
sensitivity), the gold-standard method, is time consuming as 4–
8 weeks is required for visible colonies to appear (Reichman
and Hersfield, 1993; Sia and Wieland, 2011). The availability of
commercial automated rapid molecular tests (Xpert R© MTB/RIF)
has overcome this problem, providing results within 2 h and
showing moderate to high accuracy (61.1–100% sensitivity; 90.9–
100% specificity; Rachow et al., 2011). However, the use of any of
these tests to investigate suspected cases of pulmonary TB is more
complicated if sputum is of low quality or quantity, routinely
requiring a bronchoscopy with bronchoalveolar lavage (Khalil
and Butt, 2015). Thus, the global search for fast, more accurate
and non-invasive diagnostic biomarkers for TB continues.
As the transcription of genes is a very dynamic process,
modulation of their expression is the first major regulatory
change in many biological processes (Riedmaier and Pfaﬄ, 2013).
Correspondingly, prominent gene expression regulation has been
found in blood cells of patients with pulmonary TB or LTBI
(Berry et al., 2010; Lu et al., 2011; Maertzdorf et al., 2011,
2012; Bloom et al., 2013; Anderson et al., 2014; Esterhuyse
et al., 2015; Laux da Costa et al., 2015; Zak et al., 2016).
The potential applications of biomarkers for TB include not
only the improvement of the current diagnostic tests, but also
the possibility of assessing the response to drug therapy and
targeted screening of eligible subjects for new TB vaccines and
therapeutic trials. However, most previous exploratory attempts
are based on array techniques for mRNA expression, which may
have contributed to a high redundancy among studies, usually
revealing mRNAs whose products correlate with the human
immune response to TB: type-I and type-II interferon signaling,
Toll-like receptors, T- and B-cell functions, and neutrophil influx
(Blankley et al., 2014; Deffur et al., 2015). Moreover, even though
some of the presented biomarkers/biosignatures showed high
accuracy for TB detection, the lack of validations in cohorts
from different geographical areas and/or the proposed use of
combinations of a number of genes (from sets of 3 to 100s),
hinder their use in clinical routine.
The advent of RNA sequencing (RNAseq) technology
allowed the simultaneous measurement and profiling of the
transcriptome of a biosample, avoiding biases introduced during
microarray hybridization (Zhao et al., 2014). The aim of the
present study therefore was to identify new mRNA biomarkers
for TB in whole blood specimens. For this purpose, in an
exploratory investigation, a small set of recent close TB contacts
(rCt) exposed to a bacillary index case, and TB patients, were
submitted to whole blood transcriptomic profiling via RNAseq
(unpublished data); the raw transcriptome data can be found at
the NCBI Gene Expression Omnibus (GEO) under the accession
code GSE84076. Mining these data, highly prominent regulation
of DOCK9, EPHA4, and NPC2 mRNA expression was observed in
the TB samples. Following a first validation by quantitative real-
time PCR (RT-qPCR) in a cohort of rCt and TB cases from Rio de
Janeiro/Brazil, expression data from previous microarray studies
(Berry et al., 2010; Maertzdorf et al., 2012; Bloom et al., 2013) were
also used for an independent validation of these potential mRNA
biomarkers in populations with different levels of TB incidence
and diverse genetic backgrounds.
MATERIALS AND METHODS
Ethics Statements
The study protocol was approved under the registration codes
560-10, 183-10, and 190/12, by the Ethics Committee of the
Oswaldo Cruz Foundation, Clementino Fraga Filho University
Hospital (CFFUH) and Polyclinic Augusto do Amaral Peixoto
(PAAP), respectively. Participation in this study was voluntary
and only subjects ≥18 years of age who gave informed written
consent were eligible.
Participants
All participants were recruited from March 2010 to November
2013 at CFFUH and PAAP, both located in Rio de Janeiro
state, Brazil, a TB endemic area with an incidence rate of
60.9/100,000 inhabitants (Equipe Gerência de Pneumologia
Sanitária SES/RJ, 2014). Demographic characteristics were
gathered via a structured questionnaire.
According to the Brazilian Ministry of Health policy
recommendations for TB/LTBI screening, all rCt recruited
underwent a clinical exam, the Mendel-Mantoux tuberculin skin
test (TST), and chest X-ray examination at enrollment (T0).
Besides clinical and epidemiological data, the diagnostic criteria
for TB among rCt or index cases were at least one acid-fast
bacilli-positive sputum sample for M. tuberculosis and/or positive
sputum culture.
After TB was excluded, TST results were read after 72 h, and
any rCt showing an induration ≥5 mm were considered as LTBI.
The rCt TST negative individuals (TSTneg) were followed up and
retested after 12 months (T12). For those rCt showing a positive
TST (TSTpos) or conversion (increase in induration of the TST
reaction of at least 10 mm) at any time-point, a free-of-cost
prophylactic treatment for LTBI (tLTBI) was offered, as well as
the appropriate treatment for individuals who developed TB (TB
progressors).
For the pilot RNAseq investigation a group of rCt from
the Brazilian cohort was stratified according to the response
to both TST and in house interferon-gamma release assays
(IGRAs) under ESAT6:CFP10 stimulation (Araujo et al., 2014).
Control and LTBI groups comprised 12 and 16 participants with
TSTneg/IGRAneg or TSTpos/IGRApos, respectively. Six confirmed
TB cases were also included.
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The validation by RT-qPCR was performed using a larger
cohort of rCt where IGRA results were not available. As the
participants presented different baseline and follow-up responses
to TST, they were allocated into groups according to the
probability of having LTBI: (i) G.I (n = 12), very low: no TST
reaction (0 mm) at baseline and at any of the follow up retests;
(ii) G.II (n = 24), low to moderate: baseline TSTneg (0–4 mm)
who did not return for skin test re-evaluation (16/24, 67%)
or converted to TSTpos (8/24, 33%); and (iii) G.III (n = 48),
high: baseline TSTpos (TST > 5 mm). The majority of TB
samples (26/45, 58%) were from treatment-naive participants,
and together with those treated ≤2 days comprise the group
G.IV (n = 29). G.V (n = 12) comprises samples from TB cases
with 3–6 days of anti-TB treatment, and G.VI consists of samples
from TB cases with 7 days (n = 2) or 6 months (n = 2) of
anti-TB treatment. Characteristics of all study participants are
summarized in Table 1.
Specimen Collection and RNA Isolation
Peripheral whole blood was collected in Paxgene RNA tubes
(PreAnalytiX, SWZ) and stored at −70◦C until processing.
Total RNA was isolated using the PAXgene Blood miRNA
Kit (PreAnalytiX, SWZ), which is indicated for the isolation
and purification of total RNA longer than 18 nucleotides.
The manufacturer’s instructions were followed at both
stages. Total RNA was quantified with a Nanodrop ND-
1000 spectrophotometer (Thermo Scientific, EUA) and RNA
integrity was assessed via agarose gel electrophoresis.
cDNA Synthesis and RT-qPCR
DOCK9, EPHA4, and NPC2 mRNAs were selected for further
validations. Total RNA (100 ng) was reverse transcribed
into complementary DNA (cDNA) using the oligo (dT)
primer and Superscript III kits (Invitrogen, Life Technologies,
USA), according to the manufacturer’s protocol. RT-qPCR was
performed as previously reported (Guerreiro et al., 2013), with
minor modifications in the master mix preparation: 0.4 µL
(250 nM) of gene-specific primers (Supplementary Table S1);
10 µL of Fast SYBR green (Applied Biosystems, Molecular
Probes, Inc.); 2 µL of cDNA; and 7.6 µL of sterile DNase-,
RNase-, and DNA-free water. All RT-qPCR tests were performed
in duplicate, assayed and analyzed in a blind manner.
RT-qPCR Relative Expression Analysis
Individual expression of DOCK9, EPHA4, and NPC2 mRNAs
was obtained as crossing point (Cp) values (Guerreiro et al.,
2013), which were subsequently normalized to RPL13A mRNA
expression, using the qPCR library (Ritz and Spiess, 2008) for
the R statistical package 3.2.3 (R Development Core Team, 2014),
resulting in relative expression data for the three target genes.
Microarray Reanalysis
Whole blood normalized microarray expression data from HD,
LTBI and pulmonary TB adults (≥18 years of age) available at
the GEO under accession number GSE19491 (Berry et al., 2010),
GSE34608 (Maertzdorf et al., 2012), and GSE42826 (Bloom et al.,
2013) were exported to Prism 6 (GraphPad Software) using the
GEO2R (Barrett et al., 2013) web tool. Follow up data during anti-
TB treatment were also available in Berry et al. (2010).
Statistical Analysis
Differences among biological groups were assessed with the
Mann–Whitney (two groups) or Kruskal–Wallis (more than
two groups) tests followed by Dunn’s multiple comparison tests
correction, when applicable. The Friedman test was applied to
analyze follow up data. p-values ≤ 0.05 and q-values < 0.01
were considered as significant. Mean, median, standard deviation
(SD), dispersion plots, AUROC (area under the receiver
operating characteristics curve) values and 95% confidence
intervals (CI) were computed using Prism 6 (GraphPad
Software); while the R statistical package 3.2.3 (R Development
Core Team, 2014) was used for the ROC (receiver operating
characteristics) curves (Robin et al., 2011), classification tree
analysis (Therneau et al., 2015), and Venn diagrams (Chen and
Boutros, 2011). Cut-off points were selected by fixing specificities
TABLE 1 | Clinical and demographic characteristics of the study population.
Groups n Age1 (SD) Males (%) TST (T0)2 TST (T4 or T12)2 Abnormal
Chest X-ray
Symptoms of
TB
Sputum-smear/(and/or)
culture positive cases
Probability of LTBI
G.I Very low 12 38.3 (16.2) 1 (8.3) 0 0 0 0 0/0
G.II Low/moderate 24 40.1 (15.5) 6 (25) 0–4 ND or ≥5 mm 0 2 0/0
G.III High 48 41.9 (14.9) 14 (29) ≥5 – 6 12 0/0
TB (days after treatment onset)
G.IV 0–2 29 39.4 (14.9) 14 (48) – – 29 29 18/18
G.V 3–6 12 43.6 (13.1) 8 (67) – – 12 12 10/6
G.VI ≥ 7 4 47.5 (20.1) 3 (75) – – 2 4 4/03
Total 129 41.1 (14.9) 46 (36) – – 49 59 –
The recent close tuberculosis (TB) contacts (rCt) and pulmonary TB patients were stratified according to the probability of latent TB infection (LTBI), via tuberculin skin
test (TST) response at enrollment (T0) and follow up (T4 or T12), or the time (days) relapsed between the anti-tuberculosis treatment onset and the blood collection for this
study, respectively.
1Mean age and standard deviation (SD), in years. 2TST in millimeters; Follow up TST in the 4th or 12th consecutive month. 3At the time of diagnostic. ND, not done.
Frontiers in Microbiology | www.frontiersin.org 3 October 2016 | Volume 7 | Article 1586
fmicb-07-01586 October 22, 2016 Time: 15:41 # 4
de Araujo et al. NPC2 mRNA As Biomarker for Tuberculosis
FIGURE 1 | Receiver operating characteristic (ROC) curve analysis and the respective areas under the curve (AUC) with 95% confidence intervals
(blue), comparing peripheral blood DOCK9, EPHA4, and NPC2 gene expression profiles, obtained via RNA sequencing, between recent close
tuberculosis (TB) contacts (rCt, n = 28) and patients with pulmonary TB (n = 6) for the screening of target genes for Mycobacterium tuberculosis
infection.
≥90%, after which relative expression of each gene was classified
as low (below the cut-off) or high (above the cut-off).
RESULTS
Target-Genes Screening via RNAseq
The proposed groups for this pilot investigation did not differ
significantly in age (mean age [SD], in years: control: 42.1
[14.4]; LTBI: 45.5 [12.7]; and TB: 44.9 [13.2], p = 0.202).
A predominance of women among control (10/12, 83%) and
LTBI (10/16, 63%) groups compared to the active TB cases (2/6,
33%) was observed.
The group with active pulmonary TB was used as reference
of infection for biomarker screening. Compared to control
and LTBI groups, 120 and and 52 genes, respectively, were
differentially expressed in the TB cases. From these sets of
genes, 13 mRNAs (ANKRD22, APOL4, BANK1, BATF2, DHRS9,
DOCK9, EPHA4, ETV7, FAM26, FMN1, NPC2, NT5E, and
WARS) were found in both comparisons (TB vs. LTBI or
controls). Then, as the highest AUROC (≥0.94) were observed
for DOCK9, EPHA4, and NPC2 (Figure 1), these three genes were
selected for further validations.
Gene Expression Profiling via RT-qPCR:
The Brazilian Cohort
The assay was performed in 129 participants comprising 45 TB
patients and 84 rCt. The majority of the TB cases were confirmed
by a positive sputum smear and/or culture (G.IV = 27/29 [93%];
G.V= 10/12 [83%]; G.VI= 3/4 [75%]). Clinical examination and
free-of-cost treatment for LTBI/TB was offered at baseline and
during follow up, but 35% (29/84) of the rCt did not return for
re-evaluation. The mean age [SD] of the recruited rCt (41 [15.1]
years) and TB (41 [14.9] years) participants was not significantly
different (p = 0.787). Most of the TB patients were males (rCt:
21/84, 25%; TB: 25/45, 56%) with abnormal findings on chest
x-ray (rCt: 6/84, 7%; TB: 45/45, 100%) and clinical symptoms of
TB (rCt: 14/84, 17%; TB: 43/45, 96%; Table 1).
Gene expression profiling of EPHA4 and NPC2 showed
a tendency of gradual median increment from G.I to G.IV,
decreasing toward G.V and G.VI (Supplementary Table S2).
Hence, in multiple group comparisons, only EPHA4 and NPC2
offered significant, or borderline, differences between controls
(G.I) and latently (G.III) or actively infected groups (G.IV)
(Figures 2B–D). Interestingly, a bimodal expression profile was
observed for DOCK9 and EPHA4 especially in group G.IV
(Figures 1 and 2B).
NPC2 presented the most significant differential expression, as
mRNA levels in controls (G.I) were significantly lower than in the
other groups (p < 0.05), except for TB with >7 days of specific
treatment (G.VI, p > 0.999). Moreover, up-regulation of NPC2,
with consistent changes in median expression, was observed in
active disease (G.IV, p≤ 0.001) compared to rCt with high (G.III,
p < 0.05) or low-to-moderate (G.II, p = 0.06) probability of
infection (Figure 2D).
RT-qPCR: ROC Curve Analysis
Receiver operating characteristic curve analysis demonstrated
that relative expression of NPC2 mRNA had the highest
discriminatory power for detection of LTBI (G.III,
AUROC= 0.79, 95% CI= 0.65–0.92), TB (G.IV, AUROC= 0.88,
95% CI = 0.77–0.99), or both active and latent infections (G.III
+ G.IV, AUROC = 0.82, 95% CI = 0.72–0.93), followed by
EPHA4 (LTBI, G.III: AUROC = 0.70, 95% CI = 0.53–0.87; TB,
G.IV: AUROC = 0.73, 95% CI = 0.56–0.90; and both G.III
+ G.IV: AUROC = 0.720, 95% CI = 0.56–0.88) and last by
DOCK9 (LTBI, G.III: AUROC = 0.59, 95% CI = 0.40–0.79; TB,
G.IV: AUROC = 0.66, 95% CI = 0.46–0.86; and both G.III +
G.IV: AUROC = 0.63, 95% CI = 0.43–0.82) (Supplementary
Figure S1).
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FIGURE 2 | Relative expression of DOCK9, EPHA4, and NPC2 mRNAs
in whole blood, as obtained with quantitative real-time PCR
(RT-qPCR). RPL13A mRNA was used as reference (housekeeping) gene. All
participants were recruited from the broad population of routine clinical
practice at public hospitals in Rio de Janeiro/Brazil. Data are shown as
median ± interquartile range. (A) Comparison between all healthy recent close
TB contacts (rCt) and patients with pulmonary tuberculosis (TB).
Mann–Whitney U-test; ∗p < 0.05 and ∗∗∗p < 0.001. (B–D) Comparison
between healthy recent close TB contacts (rCt) stratified in three groups
according to probability of latent tuberculosis infection: (G.I, n = 12) very low,
(G.II, n = 24) low to moderate, and (G.III, n = 48) moderate to high; and
tuberculosis (TB) cases grouped by the time elapsed between the anti-TB
treatment onset and the blood collection for this study (G.IV: 0–2 days,
n = 29; G.V: 3–6 days, n = 12; and G.VI: ≥7 days, n = 4). (B) DOCK9,
(C) EPHA4, and (D) NPC2 gene expression. The Kruskal–Wallis test was used
to access significance of global differences across groups (DOCK9 p = 0.039,
EPHA4 p = 0.059 and NPC2 p < 0.0001), among rCt (DOCK9 p = 0.276,
EPHA4 p = 0.079 and NPC2 p = 0.005) or TB (DOCK9: p = 0.18; EPHA4:
p = 0.38; and NPC2: p = 0.28), followed by Dunn’s Multiple Comparison test
(∗p < 0.05, ∗∗p ≤0.005, and ∗∗∗p ≤ 0.001).
Remarkably, in single gene analysis NPC2 mRNA expression
levels showed the highest discrimination, detecting 86% (25/29)
of the TB (G.IV) patients and only one control (1/12),
corresponding to 92% specificity (Table 2). Therefore, using
NPC2high expression for screening, in conjunction with the
available clinical/radiological findings, allowed to differentiate
latent and active forms of infections: G.I= 0/12 (0%), G.II= 0/24
(0%), G.III= 2/48 (4%), G.IV= 25/29 (86%), G.V= 8/12 (67%),
G.VI = 1/4 (25%) (Figure 3). The use of combinations of the
three mRNAs and/or other available epidemiological data did not
improve classifying capability any further.
RT-qPCR: Follow up Analysis
Among all rCt showing an NPC2high expression profile
(NPC2high/total: G.I = 1/12 [8.3%], G.II = 13/24 [54.2%], and
G.III = 29/48 [60.4%]; total = 43/84 [51%]), the majority
accepted the prophylactic treatment for LTBI (tLTBI/NPC2high:
G.I = 0/1 [0%]; G.II = 4/13 [31%]; G.III = 25/29 [86%];
total = 29/43 [67%]). Of note, among all untreated rCt (n = 41),
a single subject in G.III progressed to active TB during follow up
TABLE 2 | Receiver operating characteristic (ROC) analysis of normalized
expression values, via quantitative real-time PCR, to classify recent close
TB contacts from G.I (low probability of latent tuberculosis infection) and
patients with tuberculosis (G.IV) in the Brazilian cohort.
Gene AUC Sensitivity (%) Specificity (%) Cut-off
pointU
[95% CI]
DOCK9 0.66 [0.46–0.86] 19 [7–39] 91.7 [62–100] >0.481
EPHA4 0.73 [0.56–0.90] 53.4 [33–73] 91.7 [62–100] >0.160
NPC2 0.88 [0.77–0.99] 84.6 [65–96] 91.7 [62–100] >0.133
Unormalized expression values.
(Supplementary Table S3). The mRNA expression profile of this
participant was high only for NPC2 at T0 (DOCK9: 0.070, EPHA4:
0.121 and NPC2: 0.248), which was even higher upon diagnosis
of TB (DOCK9: 0.076, EPHA4: 0.247 and NPC2: 0.309) and
decreased after the anti-TB treatment (DOCK9: 0.019, EPHA4:
0.065 and NPC2: 0.152) (Supplementary Figure S2). None of the
NPC2low participants progressed to active TB during the period
of this study.
Microarray Reanalysis: Cross-Sectional
Studies
All reanalyzed cohorts showed significant (p< 0.001) differential
expression of EPHA4 and NPC2 mRNAs in whole blood of TB
patients (Figures 4A–D). Specificities were high (≥94%) for all
selected genes. In ROC curve analysis, again, the highest AUROC
values (≥0.95) were observed for NPC2 mRNA, corresponding
to sensitivities between 82% (95% CI 66%–93%) and 100% (95%
CI 63%–100%), followed by EPHA4, AUROC from 0.79% (95%
CI 0.66%–0.91%) to 0.92% (95% CI 0.85%–1.0%), with poor-to-
moderate sensitivities: 23.5% (95% CI 11%–41%) to 75% (95%
CI 51%–91%) (Table 3). On the other hand, DOCK9 mRNA,
AUROC from 0.53% (95% CI 0.28%–0.82%) to 0.93% (95% CI
0.84%–1.0%), usually showed low sensitivities, from 13% (95% CI
3%–57%) to 35% (95% CI 15%–59%), except for the Bloom et al.
(Bloom et al., 2013) study (82%, 95% CI 48%–98%) (Table 3).
Microarray Reanalysis: TB Treatment
follow up
Reanalyzing microarray blood expression data from TB patients
(n = 7) at enrollment (T0), and at T2 and T12 (elapsed time
in months) after initiation of antimycobacterial treatment, we
noticed a gradual trend of up-regulation of DOCK9 (p = 0.08)
and EPHA4 mRNA (p = 0.0003), and down-regulation of NPC2
(p = 0.004), during follow up (Figure 5). Even though DOCK9
and EPHA4 showed bimodal gene expression profiles among
HD (n = 12) and TB-T12 groups, no statistical differences were
observed between these groups for all target genes (Mann–
Whitney U-test, p≥ 0.415) and, notably, the NPC2high biomarker
was the only one that normalized completely 12 months after the
onset of anti-TB treatment.
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FIGURE 3 | Classification tree using relative expression of NPC2 mRNA by RT-qPCR (cut-off 0.133) in conjunction with clinical and radiological
information. Latent TB infection probability groups: G.I very low, G.II low to moderate, and G.III moderate to high; and patients with active pulmonary tuberculosis
(TB) grouped by the time (days) elapsed between the anti-TB treatment onset and the blood collection for this study (G.IV: 0–2 days; G.V: 3–6 days; and G.VI:
≥7 days).
DISCUSSION
Previous whole blood genomic-scale studies pointed to a 144
(Bloom et al., 2013) or 393 (Berry et al., 2010) gene-transcript
signature (including DOCK9 and EPHA4) for TB, showing
61.7–94.1% sensitivities and 93.8–97% specificities (Berry et al.,
2010; Bloom et al., 2013). Nevertheless, the use of 100s of
genes for transcriptional profiling in clinical practice is currently
impractical. Lu et al. (2011) proposed a smaller combination
of genes, CXCL10, ATP10A and TLR6, which showed 71%
sensitivity and 89% specificity to discriminate between latent
and active TB. Lee et al. (2016) with a similar objective showed
excellent AUROC ( = 1.0) for the comparisons between LTBI
(n= 7) or active TB (n= 7) vs. HD (n= 7) using peripheral blood
ASUN or PTPRC mRNA levels. Even though this accuracy was
independently validated (AUROC ≥ 0.94), the assayed cohort
had a small sample size (15 TB, 17 LTBI, and 15 HD; Lee
et al., 2016). In a separate study, gene expression differentiation
between TB and other pulmonary diseases was also described,
which was based on another set of three genes (GBP5, GZMA,
and CD64) and had a 93% sensitivity and 95% specificity;
Laux da Costa et al., 2015). More recently, Zak et al. (2016),
in a prospective African contact tracing study that featured a
study design similar to ours (RNAseq for target-gene screening
and RT-qPCR for biomarker validation), proposed a 16 gene-
based transcriptional biosignature for risk of disease progression
with 80.6% specificity, but with low sensitivity (66.1%) in the
12 months preceding TB diagnosis.
In the present study, we describe, for the first time, an up-
regulation of NPC2 mRNA levels in the blood of tuberculous
subjects, as well as the transcription profiles of DOCK9, EPHA4
and NPC2 among Brazilians recently exposed to a TB index case.
As 25% (1/4) of the untreated subjects from G.III progressed to
active TB during the 1-year follow up period (Supplementary
Table S3), the prophylactic treatment might have compromised
the evaluation of the proposed biomarker in the early detection of
TB. Another limitation of this study is the lack of an unexposed
control group among the Brazilian donors. However, in high
FIGURE 4 | Reanalysis of DOCK9, EPHA4, and NPC2 expression in
whole blood from healthy donors (HD), latently infected subjects (LTBI)
and patients with pulmonary tuberculosis (TB) based on the data
published by Berry et al. (2010), Maertzdorf et al. (2012), and Bloom
et al. (2013). The previous microarrays studies were performed in cohorts
from: (A) UK (HD = 24, LTBI = 38, TB = 24), (B) South Africa (LTBI = 31,
TB = 20), (C) Germany (HD = 18, TB = 8), and (D) UK/France (HD = 52,
TB = 11), respectively. Mann–Whitney U or Kruskal–Wallis tests were
performed for two or >2 groups comparisons, respectively (∗∗p ≤ 0.005 and
∗∗∗p < 0.001). Small lines, dotted lines and bars represent the median, cut-off
and ±interquartile range, respectively.
TB-burden scenarios, as Rio de Janeiro/Brazil, it is difficult to rule
out a previous exposure to M. tuberculosis, even in subjects with
no reported contact with a TB index case. To overcome this, we
opted to group the enrolled participants according to baseline
and follow up response to TST, a highly sensitive LTBI test
(Schluger and Burzynski, 2010), and evaluated HD expression
profiles in other cohorts. Notably, a one-gene biosignature,
NPC2high, showed high sensitivity (85%) and specificity (92%),
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TABLE 3 | Receiver operating characteristic curve reanalysis of deposited microarray expression data for DOCK9, EPHA4, and NPC2, to classify healthy
donors (HD) and tuberculosis (TB) cases in cohorts from the UK, South Africa, Germany, and France.
Study site (reference)
UK† (2) South AfricaU (2) Germany (5) UK /France (6)
Gene n Value [95% CI] n Value [95% CI] n Value [95% CI] n Value [95% CI]
DOCK9 AUC (HD vs. TB) 0.79 [0.66–0.92] 0.80 [0.66–0.95] 0.53 [0.28–0.82] 0.93 [0.84–1.0]
Specificity (%) 24 96 [79–100] 31 97 [83–100] 18 94 [73–100] 52 96. [87–100]
Sensitivity (%) 34 15 [5–31] 20 35 [15–59] 8 13 [0.3–53] 11 82 [48–98]
EPHA4 AUC (HD vs. TB) 0.79 [0.66–0.91] 0.92 [0.85–1.0] 0.85 [0.69–1.0] 0.90 [0.79–1.0]
Specificity (%) 24 96 [79–100] 31 97 [83–100] 18 94 [73–100] 52 962 [87–100]
Sensitivity (%) 34 24 [11–41] 20 75 [51–91] 8 63 [25–92] 11 55[23–83]
NPC2 AUC (HD vs. TB) 0.95 [0.91–1.0] 0.97 [0.93–1.0] 0.99 [0.95–1.0] 0.99 [0.97–1.0]
Specificity (%) 24 96 [79–100] 31 97 [83–100] 18 94 [73–100] 52 96 [87–100]
Sensitivity (%) 34 82 [66–93] 20 85 [66–97] 8 100 [63–100] 11 91 [58–100]
†Study population composed of immigrants from endemic countries or household contacts.
UHD samples were not available; therefore, ROC analysis was performed comparing latently infected subjects and TB patients.
FIGURE 5 | Twelve months follow up of DOCK9, EPHA4, and NPC2 expression after initiation of anti-TB treatment. Pulmonary tuberculosis (TB, n = 7)
was confirmed by isolation of M. tuberculosis upon culture of sputum or bronchoalvelolar lavage fluid. Samples from healthy donors (HD, n = 12) without known
exposure to TB who were negative by both tuberculin skin test and interferon-gamma release assay were also included in the analysis. Whole blood samples from
TB patients were collected prior to the initiation of the anti-mycobacterial therapy (TB-T0), in the second (TB-T2) and twelfth (TB-T12) consecutive months. Short bars
represent medians. Reanalyzed data from Berry et al. (2010).
via RT-qPCR, for TB detection. In addition, a reanalysis of
expression data from public repositories showed a similar
sensitivity (82–100%) and specificity (94–97%) in populations
with different genetic backgrounds (Berry et al., 2010; Maertzdorf
et al., 2012; Bloom et al., 2013).
Here, the monitoring of NPC2 mRNA levels in blood could
be used as a screening tool for the detection of active TB.
On the other hand, by RT-qPCR or microarray reanalysis,
DOCK9 (13–82%) and EPHA4 (24–75%) usually showed poor-
to-moderate sensitivities but, interestingly, they exhibited a
dichotomous median expression profile among the different
TB groups in comparison to the respective control: down-
modulation in populations from the UK and South Africa
(Figure 4), but the contrary among Brazilians (Figures 2B,C) and
Germans (Figure 4C). A bimodal DOCK9 and EPHA4 mRNA
expression profile was also observed, principally in the TB groups
from Brazil (G.IV and G.V, Figures 2B,C), UK cross-sectional
(Figure 4D) and the follow up cohorts (Figure 4). This bimodal
transcription, in response to physiological disturbances, was
previously described for other genes (Bessarabova et al., 2010).
Furthermore, according to Bessarabova et al. (2010) the presence
of a bimodal gene expression profile could correspond to different
disease subtypes. Thus, further studies are needed to assess
whether different M. tuberculosis strains, infection sites, previous
infections, host genetic background or co-morbidities can affect
DOCK9 and EPHA4 mRNA expression profiles. Interestingly,
this bimodal behavior was not observed for NPC2.
Anti-TB chemotherapy usually requires a 6-months standard
regimen to eradicate the infection (Jindani et al., 2004). The
observed change trend in the median expression levels for all
target genes toward an uninfected control-like transcriptional
profile, in the beginning of treatment (G.VI, Figure 2), and more
pronounced in the TB-T12 group (Figure 3), is an indication that
these modulations are dependent on the presence of viable bacilli
in the host system.
The exact physiological role of the dedicator of cytokinesis
9 (Dock9) protein has not been totally defined yet. According
to Gadea and Blangy (2014), it is possible that Dock9 plays
a role in the activation of Cdc42, a Rho GTPase that can
affect TGF-beta1-mediated transcriptional responses. Dock9 has
also been implicated in the epithelial to mesenchymal cell
transition through the reorganization of the actin cytoskeleton
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and the regulation of cell polarity (Brown et al., 2008; Gadea and
Blangy, 2014). Previous studies have pointed to the role of Epha4
and its receptor, Ephrin A1, in the process of lymphocyte and
monocyte adhesion (Poitz et al., 2015). The Eph/Ephrin-system,
among others, was described to influence Rho GTPases, such as
Cdc42 (Singh et al., 2012). Taken together, these observations
suggest that these proteins have a common pathway in the
recruitment of immune cells to M. tuberculosis infection sites.
NPC2 plays roles in cholesterol and glycolipid trafficking
and/or transport, and mutations in it are causally related
to Niemann-Pick disease, a life-threatening lysosomal storage
disease (Park et al., 2003), but studies on its role in M. tuberculosis
pathogenesis are scarce. Recently, knockdown experiments
demonstrated that adding all-trans retinoic acid (ATRA), the
biologically active form of vitamin A, to M. tuberculosis-
infected human monocyte cultures resulted in an NPC2-
dependent decrease in total cellular cholesterol, associated
with a consequent increase in antimicrobial activity through
lysosomal acidification (Wheelwright et al., 2014). The authors
postulated that decreasing levels of NPC2 expression might favor
M. tuberculosis persistence. In contrast, we observed an up-
regulation of NPC2 mRNA in whole blood from patients with
active TB and LTBI subjects, indicating that increased NPC2
expression is part of the host response to TB infection but
does not confer protection in all cases. As we could observe
in the incident case (Supplementary Figure S2), and in the
subcohort of NPC2high TB patients in whom disease progression
could not be prevented, expression of this gene was still high.
Our data indirectly demonstrate that upon the persistence of
M. tuberculosis, systemic modulation of gene expression may
occur even in asymptomatic, but latently infected subjects.
Nonetheless, it is still necessary to investigate which genotypic
or phenotypic features could be responsible for the NPC2low
expression profile in a few TB patients. Moreover, it is also
necessary to clarify whether NPC2 up-regulation is specific for
TB infection among patients with respiratory symptoms. In
two of the reanalyzed studies (Maertzdorf et al., 2012; Bloom
et al., 2013) samples from other pulmonary diseases were also
included (data not shown). The NPC2high blood expression
profile was detected in only 1/6 (17%) pneumonia patients and
1/8 (13%) lung cancer patients (Bloom et al., 2013) but, in
50% (n = 9/18) (Maertzdorf et al., 2012) and 56% (n = 9/16)
(Bloom et al., 2013) of patients with active sarcoidosis. As
sarcoidosis is a low incidence disease (Nunes et al., 2007),
of which M. tuberculosis is a possible aetiological agent (van
Enschot and van Balkom, 2013), the observed relatively frequent
detection of the NPC2high biomarker should not compromise
the application of this marker for the screening of active TB
cases.
Considering the limitations of available routine methods
for screening of M. tuberculosis infection among respiratory
symptomatic or asymptomatic individuals, which hamper the
control of this important illness, the profiling of NPC2 mRNA
expression in blood seems to be an attractive alternative,
since it has demonstrated an excellent accuracy using a fast
methodology such as RT-qPCR for single-gene quantification
in blood specimens. The additional similar results, obtained
with populations of various genetic backgrounds and from
different TB-burden scenarios, encourage us to stress the need
for further validations of this biomarker in new cohorts,
evaluating its modulation during disease progression and
treatment success. In the meantime, the roles of DOCK9,
EPHA4, and NPC2 genes in TB pathogenesis also merit further
investigations.
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